Posted on 2/9/17
After Copaxone, Is Teva's Future Bleak?
Teva Pharmaceutical (NYSE:TEVA) has its hands full. Its peers are challenging patents protecting its best-selling drug, Copaxone, and that puts billions of dollars at risk. However, . . .
Posted on 2/9/17
Why Celldex Therapeutics Stock Fell by Almost 10% in January
What happenedAccording to data from S&P Global Market Intelligence, shares of the clinical-stage biotech Celldex Therapeutics (NASDAQ:CLDX) slid by 9.7% in January and did so without . . .
Posted on 2/9/17
Synchronoss Technologies Moves Forward After Intralinks Acquisition
The pitfall of quarterly reporting is that it tends to focus investor attention on short-term thinking. For Synchronoss Technologies (NASDAQ:SNCR), the boom in cloud computing is . . .
Posted on 2/9/17
Interpace Diagnostics Closes $3.9 Million Public Offering
Interpace Diagnostics Group, Inc. (IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced the closing of its . . .
Posted on 2/9/17
Helius Medical Technologies Proposes Public Offering of Class A Common Stock
Helius Medical Technologies, Inc. (TSX: HSM, OTCQB: HSDT) announced today that it intends to offer and sell, subject to market conditions, shares of its class A common . . .
Posted on 2/8/17
Better Buy: Merck & Co. Inc. vs. GlaxoSmithKline
They're two of the biggest pharmaceutical companies in the world, but Merck (NYSE:MRK) and GlaxoSmithKline (NYSE:GSK) have had very different paths lately. While Merck's stock is . . .
Posted on 2/8/17
Better Buy: Kimberly-Clark Corporation vs. Johnson & Johnson
As long-term investments, it's hard not to like dividend giants Kimberly-Clark (NYSE:KMB) and Johnson & Johnson (NYSE:JNJ). They both enjoy prime market positions that deliver unusually . . .
Posted on 2/8/17
Teva Q4 Earnings: Brace For Impact
ThesisTeva pharmaceuticals (NYSE:TEVA) is one of the pharmaceutical companies that have been under significant scrutiny because of their price hiking. The company missed the latest two . . .
Posted on 2/8/17
Johnson & Johnson Needs To Paint A Heartening Picture With Canvas
Johnson & Johnson’s (NYSE:JNJ) diabetes therapy Invokana needs a strong result in its cardiovascular outcomes trials this year if it is to hold off the threat . . .
Posted on 2/8/17
Why Teva Pharmaceuticals Industries Just Lost $1.5 Billion In Market Value
What happenedAfter announcing the sudden departure of its CEO, shares of Teva Pharmaceuticals (NYSE:TEVA), an Israeli-based manufacturer of generic and branded drugs, fell by more than . . .
Posted on 2/6/17
ICTV Brands Completes $7M Common Stock Financing
ICTV Brands, Inc. (OTCQX: ICTV) (CSE: ITV), a digitally focused, direct response marketing and branding company specializing in the health, wellness and beauty sector, today announced . . .
Posted on 2/6/17
Pfizer May Be Another IBM
IntroductionOh, how the mighty Big Pharma dinosaurs have fallen, or at least are stumbling. Maybe Pfizer (NYSE:PFE) has not actually fallen, but if so, it's because . . .
Posted on 2/6/17
Pfizer's New Biosimilar Is Off and Running
Pfizer, Inc. (NYSE:PFE) launched Inflectra, its biosimilar to Johnson & Johnson's (NYSE:JNJ) Remicade, late last year, and fourth-quarter earnings reports from the two companies provide us . . .
Posted on 2/6/17
Johnson & Johnson Just Raised The Bar For Pharma M&A, Just As The Sector Comes To Life
Recently, the Large Pharma CEOs met with President Trump, which went better than the market anticipated. That paved the way for a broader healthcare and biotech . . .
Posted on 2/6/17
Merck: Analyzing 2016 Performance And Outlook For 2017
On February 2, Merck (NYSE:MRK) reported fourth-quarter results that met analyst forecasts on earnings, but missed on revenue. However, the miss was only by a slight . . .
Posted on 2/6/17
Johnson & Johnson Is Becoming a Far Riskier Investment
CEO ALEX GORSKY. IMAGE SOURCE: JOHNSON & JOHNSON.By all accounts, healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is one of the steadiest, safest stocks that long-term investors . . .
Posted on 2/6/17
Palatin Technologies Closes License Agreement with AMAG Pharmaceuticals
Palatin Technologies, Inc. (NYSE MKT: PTN) announced the closing of its license agreement with AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) for exclusive North American rights to develop . . .
Posted on 2/6/17
Interpace Diagnostics Prices Public Offering to Raise $3.6 Million
Interpace Diagnostics Group, Inc. (IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced the pricing of an . . .
Posted on 2/3/17
Pernix Therapeutics Provides Update on Arbitration
MORRISTOWN, N.J., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today . . .
Posted on 2/3/17
Interpace Diagnostics Proposes Public Offering of Common Stock
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, today announced that it intends . . .
Posted on 2/3/17
Nestlé to Expand Manufacturing Capacity at Eau Claire Plant
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Building on its commitment to local American communities, Nestlé today announced that it intends to expand its manufacturing facility in Eau Claire, WI. . . .
Posted on 2/2/17
Hemispherx Biopharma Announces $1 Million Registered Direct Offering
PHILADELPHIA, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB), announced today that it has entered into definitive agreements with several institutional investors for . . .
Posted on 2/2/17
5 Things Pfizer's Management Wants You to Know
Pfizer (NYSE:PFE) might have fallen short of expectations with its fourth-quarter earnings results, but the market didn't seem to mind. The big drugmaker's shares were up . . .
Posted on 2/2/17
3 Pharmaceutical Stocks With Bigger Dividends Than Johnson & Johnson
If there were such a thing as the dividend stock hall of fame, Johnson & Johnson(NYSE:JNJ) would be in it. After all, the company increased its . . .
Posted on 2/2/17
Safeguard Scientifics: Heading To The Future With Internet Of Everything, AI And Cybersecurity
Safeguard Scientifics Inc. (NYSE:SFE), located outside Philadelphia, is a private equity and venture capital firm that came on the scene in 1953 and now invests in . . .

